Perrigo Company plc Payment for Debt Extinguishment or Debt Prepayment Cost
Perrigo Company plc (PRGO) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2023-11-07
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-09-30 was $0.00.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-10-01 was $0.00.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for the quarter ending 2021-10-02 was $0.00.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for the quarter ending 2015-06-27 was $0.00.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for fiscal 2016 was $600.00K.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for fiscal 2015 was $0.00.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for fiscal 2013 was $0.00.
- Perrigo Company plc payment for debt extinguishment or debt prepayment cost for fiscal 2012 was $0.00.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |||
| 2023-07-01 | $0.00 10-Q · filed 2023-08-08 | ||||
| 2022-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $12.20M 10-Q · filed 2023-11-07 | |||
| 2022-07-02 | $12.20M 10-Q · filed 2023-08-08 | ||||
| 2021-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-07-03 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2020-09-26 | $19.00M 10-Q · filed 2021-11-12 | ||||
| 2019-09-28 | $0.00 10-Q · filed 2020-11-05 | ||||
| 2016-12-31 | $600.00K 10-K · filed 2017-05-22 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-05-22 | ||||
| 2015-06-27 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $0.00 derived: sum of 2 quarters · filed 2017-05-22 | $0.00 10-K · filed 2017-05-22 | ||
| 2015-03-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | $0.00 10-Q · filed 2015-04-29 | |||
| 2014-12-27 | $0.00 10-Q · filed 2015-02-05 | ||||
| 2014-06-28 | -$133.50M derived: 10-Q/A 12 month − 10-Q 9 month · filed 2017-05-22 | -$133.50M derived: sum of 2 quarters · filed 2017-05-22 | -$100.00K derived: sum of 3 quarters · filed 2017-05-22 | $0.00 10-Q/A · filed 2017-05-22 | $133.50M 10-K · filed 2014-08-14 |
| 2014-03-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | $133.40M derived: sum of 2 quarters · filed 2015-04-29 | $133.50M 10-Q · filed 2015-04-29 | ||
| 2013-12-28 | $133.40M 10-Q · filed 2014-05-07 | $133.50M 10-Q · filed 2015-02-05 | |||
| 2013-06-29 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 derived: sum of 2 quarters · filed 2016-02-25 | $0.00 10-KT · filed 2016-02-25 | ||
| 2013-03-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $0.00 10-Q · filed 2014-05-07 | |||
| 2012-12-29 | $0.00 10-Q · filed 2014-02-06 | ||||
| 2012-06-30 | $0.00 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |